Cambridge Cancer Genomics (CCG.ai), a Y combinator backed startup building the software for data-driven precision oncology, were today named winners of a Gold Stevie® Award in the “Tech Startup of the Year - Software” category at The 16th Annual International Business Awards®.
The International Business Awards are the world’s premier business awards. A record total of more than 4,000 nominations from organizations of all sizes and in virtually every industry were submitted this year for consideration, in a wide range of categories. Cambridge Cancer Genomics won Gold in the ‘Tech Startup of the Year - Software’ category. Nicknamed the Stevies for the Greek word for “crowned”, the awards will be presented to winners at a gala awards banquet at the ANDAZ Hotel am Belvedere, Vienna, Austria on 19 October.
Cambridge Cancer Genomics (CCG.ai) is on a mission to ensure that each patient has the right treatment, at the right time, to beat their cancer. Their precision Artificial Intelligence platform enables oncologists to provide more effective, personalised cancer treatment for everyone. CCG.ai’s intelligently designed algorithms analyse and interpret DNA from a cancer patient, providing genomic insights into individual tumours as they change and grow. Their technology gives actionable insights into treatment effectiveness and provides personalised treatment and trial recommendations; it also powers intelligent clinical trial design and drug development.
"It’s great to accept, on behalf of the brilliant team at CCG.ai, a Gold Stevie Award in the ‘Tech Startup of the Year - Software’ category at this year’s IBAs” says Dr. John Cassidy, CEO at CCG.ai. ”This has been an exciting year for us, and to win against such fantastic businesses is a real testament to the team we have built at CCG.ai and the technologies at our heart. Congratulations to all the nominees!”
The competition judges were impressed by CCG.ai’s AI software, stating:
“This is a great opportunity for this organization to solve one of the biggest problems of this century. Predicting therapy effectiveness is an innovative application of the technology and will pave the way for the betterment of humanity” and “A great realization to a great cause. Something that is worth more attention and will help millions in their struggle with oncology”.
Stevie Award winners were determined by the average scores of more than 250 executives worldwide who participated in the judging process from May through early August.
“The IBA judges from across the world were highly impressed with the nominations they reviewed this year. With the level of achievement documented in the nominations from 74 nations, the Stevie Awards are proud to honor organizations that demonstrate a high level of achievement in a variety of industries” said Michael Gallagher, president and founder of the Stevie Awards. “We received more nominations than ever and look forward to honoring the Stevie winners at our gala in Vienna, Austria this October.”
Details about The International Business Awards and the full list of Stevie Award winners are available at www.StevieAwards.com/IBA.
About the Stevie Awards
The Stevie Awards are conferred in seven programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at www.StevieAwards.com
About Cambridge Cancer Genomics
Cambridge Cancer Genomics (CCG.ai) is a Y Combinator backed startup building the underlying tools to empower oncologists to make the best therapeutic decisions for their patients. Their precision AI platform, OncOS, is fast becoming the global open standard for next generation sequencing analysis and clinical decision support in cancer medicine. By focussing on machine learning based analytics of serial liquid biopsy samples, CCG.ai is building predictive models to understand how tumors evolve and how this can impact on response to therapy. As this knowledge base of tumour genomic evolution increases, OncOS will become the operating system for personalised cancer medicine. At CCG.ai, our mission is to ensure every patient gets the right drug, at the right time, to beat their cancer. Learn more about CCG.ai at www.ccg.ai
For more details, or to request an interview, please contact Belle Taylor at Press@CCG.ai